Albuterol (ProAir / Ventolin / Proventil)
Short-acting beta-2 adrenergic agonist (rescue inhaler) for acute bronchospasm and asthma. Inhaled onset within 5 minutes, duration 4-6 hours. Also known as salbutamol internationally. Metabolized by oxidative deamination; ~70% excreted renally within 24 hours.
Projected serum levels — 2 puffs (≈ 0.18 mg), as needed (shown daily)
Maintenance schedule: 2 puffs (≈ 0.18 mg) as needed (shown daily) (oral).
Modeled steady state after ~1 days: peak ≈ 0.071 mg, trough ≈ 0.001 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Short-Acting Beta-2 Agonist (SABA)
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 5 h
- Common dose
- 2 puffs (≈ 0.18 mg)
- Suggested maximum
- 12 puffs/day
- Reference dose range
- 1–12 puffs (single dose)
- Suggested cadence
- as needed (shown daily)
- Validated against
- 4 mg oral — Cmax 0.018 mg/L at 2.5 h
Documented interactions
-
moderate
Epinephrine (Adrenalin) + Albuterol (ProAir / Ventolin / Proventil)
Albuterol (ProAir / Ventolin / Proventil) and Epinephrine (Adrenalin) both push the beta1 adrenergic and beta2 adrenergic in the same direction.
-
watch
Mirabegron (Myrbetriq) + Albuterol (ProAir / Ventolin / Proventil)
Albuterol (ProAir / Ventolin / Proventil) and Mirabegron (Myrbetriq) both push the beta1 adrenergic in the same direction.
-
watch
Pseudoephedrine (Sudafed) + Albuterol (ProAir / Ventolin / Proventil)
Albuterol (ProAir / Ventolin / Proventil) and Pseudoephedrine (Sudafed) both push the beta2 adrenergic in the same direction.
Serum checks 3 modeled interaction pairings for albuterol (proair / ventolin / proventil) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Active albuterol or placebo, sham acupuncture, or no intervention in asthma
NEJM trial in 46 asthma patients demonstrated albuterol produced a 20% improvement in FEV1 versus 7% for placebo, though subjective symptom improvement was similar across all groups.
-
Albuterol-budesonide fixed-dose combination rescue inhaler for asthma
Phase 3 trial of 3,132 patients with uncontrolled moderate-to-severe asthma found albuterol-budesonide rescue inhaler reduced severe exacerbation risk by 26% versus albuterol alone.
-
Regular inhaled salbutamol and asthma control: the TRUST randomised trial
RCT of 983 patients found regular scheduled salbutamol use provided no benefit over as-needed use, supporting current guidelines recommending rescue-only SABA therapy.
3 published studies referenced in the app, each with a plain-language summary.